title: Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.
abstract: Donor-derived tuberculosis (TB) is an increasingly recognized complication of solid organ transplantation. We report a case of isoniazid-resistant pulmonary TB in a lung transplant recipient. The patient acquired the infection from the lung donor who was previously empirically treated with isoniazid for latent TB. The case highlights the caveat that, while adequate treatment of latent TB with isoniazid is presumed, meticulous screening of donors is required.
authors.affiliation: Department of Infectious Diseases, St Vincent's Hospital, Sydney, New South Wales, Australia. doctomas@gmail.com.|School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia. doctomas@gmail.com.
authors.forename: T O
authors.initials: TO
authors.lastname: Jensen
authors.affiliation: Lung Transplant Unit, St Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: D R
authors.initials: DR
authors.lastname: Darley
authors.affiliation: Department of Microbiology, Sydpath, St Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: E E
authors.initials: EE
authors.lastname: Goeman
authors.affiliation: Tuberculosis Program, South Eastern Sydney Local Health District and St Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Shaw
authors.affiliation: Department of Infectious Diseases, St Vincent's Hospital, Sydney, New South Wales, Australia.|Department of Microbiology, Sydpath, St Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: D J
authors.initials: DJ
authors.lastname: Marriott
authors.affiliation: School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
authors.forename: A R
authors.initials: AR
authors.lastname: Glanville
mesh_terms: D000328:Adult; D064591:Allografts / Q000382:microbiology*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D001992:Bronchoalveolar Lavage Fluid; D001999:Bronchoscopy; D003550:Cystic Fibrosis / Q000235:genetics / Q000601:surgery*; D024881:Drug Resistance, Bacterial; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D055985:Latent Tuberculosis / Q000188:drug therapy*; D016040:Lung Transplantation / Q000009:adverse effects*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification / Q000502:physiology*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D014019:Tissue Donors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin; D007538:Isoniazid; D012293:Rifampin
keywords: isoniazid resistance; latent infection; lung transplantation; tuberculosis